Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 6, keine Gesamtzahl für „Substrates“
Suchtreffer
Begriffe & Kennungen
Ecansya (previously Capecitabine Krka) · 4.5 · Cytochrome P-450 2C9 substrates: Other than warfarin, no formal interaction studies between capecitabine and o
Eintrag öffnenEfavirenz Teva · 4.5 · Efavirenz is an in vivo inducer of CYP3A4, CYP2B6 and UGT1A1. Compounds that are substrates of these enzymes m
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Krka · 4.5 · Efavirenz is an in vivo inducer of CYP3A4, CYP2B6 and UGT1A1. Compounds that are substrates of these enzymes m
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Mylan · 4.5 · Efavirenz is an in vivo inducer of CYP3A4, CYP2B6 and UGT1A1. Compounds that are substrates of these enzymes m
Eintrag öffnenEfavirenz/Emtricitabine/Tenofovir disoproxil Zentiva · 4.5 · Efavirenz is an in vivo inducer of CYP3A4, CYP2B6 and UGT1A1. Compounds that are substrates of these enzymes m
Eintrag öffnenElebrato Ellipta · 4.5 · Fluticasone furoate, umeclidinium and vilanterol are substrates of the P-glycoprotein transporter (P-gp). The
Eintrag öffnenEmblaveo · 4.5 · In vitro, aztreonam and avibactam are substrates of organic anion transporters OAT1 and OAT3 which might contr
Eintrag öffnenEmselex · 4.5 · CYP3A4 substrates Darifenacin treatment resulted in a modest increase in the exposure of the CYP3A4 substrate
Eintrag öffnenEmselex · 4.5 · CYP3A4 substrates Darifenacin treatment resulted in a modest increase in the exposure of the CYP3A4 substrate
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEmselex · 4.5 · Effects of darifenacin on other medicinal products CYP2D6 substrates Darifenacin is a moderate inhibitor of th
Eintrag öffnenEntresto · 4.5 · OATP1B1 and OATP1B3 substrates, e.g. statins In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1
Eintrag öffnenEntresto · 4.5 · OATP1B1 and OATP1B3 substrates, e.g. statins In vitro data indicate that sacubitril inhibits OATP1B1 and OATP1
Eintrag öffnenEnyglid · 4.5 · Co-administration of cimetidine, nifedipine, oestrogen, or simvastatin with repaglinide, all CYP3A4 substrates
Eintrag öffnenEnzalutamide Viatris · 4.5 · BCRP substrates At steady-state, enzalutamide did not cause a clinically meaningful change in exposure to the
Eintrag öffnenEnzalutamide Viatris · 4.5 · CYP1A2 and CYP2C8 substrates Enzalutamide (160 mg once daily) did not cause a clinically relevant change in th
Eintrag öffnenEnzalutamide Viatris · 4.5 · MRP2, OAT3 and OCT1 substrates Based on in vitro data, inhibition of MRP2 (in the intestine), as well as organ
Eintrag öffnenEnzalutamide Viatris · 4.5 · P-gp substrates In vitro data indicate that enzalutamide may be an inhibitor of the efflux transporter P-gp. A
Eintrag öffnenEpclusa · 4.5 · Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a substrate
Eintrag öffnenEpclusa · 4.5 · Sofosbuvir and velpatasvir are substrates of drug transporters P-gp and BCRP. Velpatasvir is also a substrate
Eintrag öffnen